A Caltech Library Service

Antibody engineering for increased potency, breadth and half-life

Sievers, Stuart A. and Scharf, Louise and West, Anthony P., Jr. and Bjorkman, Pamela J. (2015) Antibody engineering for increased potency, breadth and half-life. Current Opinion in HIV and AIDS, 10 (3). pp. 151-159. ISSN 1746-630X. PMCID PMC4465343.

[img] PDF - Published Version
Creative Commons Attribution Non-commercial No Derivatives.


Use this Persistent URL to link to this item:


Purpose of review: This review highlights recent developments in HIV-1 antibody engineering and discusses the effects of increased polyreactivity on serum half-lives of engineered antibodies. Recent findings: Recent studies have uncovered a wealth of information about the relationship between the sequences and efficacies of anti-HIV-1 antibodies through a combination of bioinformatics, structural characterization and in vivo studies. This knowledge has stimulated efforts to enhance antibody breadth and potency for therapeutic use. Although some engineered antibodies have shown increased polyreactivity and short half-lives, promising efforts are circumventing these problems. Summary: Antibodies are desirable as therapeutics due to their ability to recognize targets with both specificity and high affinity. Furthermore, the ability of antibodies to stimulate Fc-mediated effector functions can increase their utility. Thus, mAbs have become central to strategies for the treatment of various diseases. Using both targeted and library-based approaches, antibodies can be engineered to improve their therapeutic properties. This article will discuss recent antibody engineering efforts to improve the breadth and potency of anti-HIV-1 antibodies. The polyreactivity of engineered HIV-1 bNAbs and the effect on serum half-life will be explored along with strategies to overcome problems introduced by engineering antibodies. Finally, advances in creating bispecific anti-HIV-1 reagents are discussed.

Item Type:Article
Related URLs:
URLURL TypeDescription CentralArticle
Bjorkman, Pamela J.0000-0002-2277-3990
Additional Information:© 2015 Wolters Kluwer Health, Inc. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License, where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially. Post Author Corrections: March 10, 2015. We thank Sonal N. Patel for help with figure preparation. This work was supported by a Collaboration for AIDS Vaccine Discovery (CAVD) grant from the Bill and Melinda Gates Foundation (Grant ID: 1040753 to P.J.B.), National Institutes of Health grant HIVRAD P01 AI100148 (P.J.B.) and award number DP10D006961 (to P.J.B.), the American Cancer Society (Grant PF-13-076-01-MPCto L.S.), California HIV/AIDS Research Program (CHRP grant F12-CT-214 to S.A.S.).
Funding AgencyGrant Number
Bill and Melinda Gates Foundation1040753
American Cancer SocietyPF-13-076-01-MPC
California HIV/AIDS Research ProgramF12-CT-214
Subject Keywords:antibody engineering; bispecific reagents; breadth; HIV-1; polyreactivity; potency
Issue or Number:3
PubMed Central ID:PMC4465343
Record Number:CaltechAUTHORS:20150317-102114582
Persistent URL:
Usage Policy:No commercial reproduction, distribution, display or performance rights in this work are provided.
ID Code:55847
Deposited By: Jason Perez
Deposited On:17 Mar 2015 18:17
Last Modified:03 Oct 2019 08:09

Repository Staff Only: item control page